Natus Medical Incorporated (NASDAQ:BABY) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersITEM 5.02.
Natus Medical Incorporated (NASDAQ:BABY) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Effective Monday, April 17, 2017, Kenneth Traverso, ceased to serve as Vice President & General Manager of Newborn Care of Natus Medical Incorporated and as a named executive officer of Natus. Mr. Traverso will remain with the Company and will lead the North American Otometrics sales and service organization.
Jonathan Kennedy, Executive Vice President and Chief Financial Officer, will assume the role and duties of General Manager of Newborn Care.
About Natus Medical Incorporated (NASDAQ:BABY)
Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders. The Company’s segment is neurology and newborn care product families. Its product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology, as well as newborn care products, such as hearing screening systems, phototherapy devices for the treatment of newborn jaundice, head-cooling products for the treatment of brain injury in newborns, incubators to control the newborn’s environment, and software systems for managing and tracking disorders and diseases for public health laboratories. It is organized into two strategic business units: Neurology and Newborn Care. Natus Medical Incorporated (NASDAQ:BABY) Recent Trading Information
Natus Medical Incorporated (NASDAQ:BABY) closed its last trading session up +0.75 at 40.15 with 225,340 shares trading hands.
Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders. The Company’s segment is neurology and newborn care product families. Its product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology, as well as newborn care products, such as hearing screening systems, phototherapy devices for the treatment of newborn jaundice, head-cooling products for the treatment of brain injury in newborns, incubators to control the newborn’s environment, and software systems for managing and tracking disorders and diseases for public health laboratories. It is organized into two strategic business units: Neurology and Newborn Care. Natus Medical Incorporated (NASDAQ:BABY) Recent Trading Information
Natus Medical Incorporated (NASDAQ:BABY) closed its last trading session up +0.75 at 40.15 with 225,340 shares trading hands.